Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease

Summary

To evaluate the efficacy of ZA oral solution in subjects with IRD caused by biallelic recessive RPE65 or LRAT gene mutations and phenotypically diagnosed as Leber's Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP).

Timeline

Start

2020-12

Primary completion

2023-02

Completion

2023-09

Outcome

Outcome not reported

Stopped: “The asset was transferred to another company”

Drugs

Indications